Shandong Xinhua Pharmaceutical Company Limited Market Cap ($132.23 Million)
Market Cap & Net Worth: Shandong Xinhua Pharmaceutical Company Limited (XIN)
Shandong Xinhua Pharmaceutical Company Limited market cap. Shandong Xinhua Pharmaceutical Company Limited (F:XIN) has a market capitalization of $132.23 Million (€113.10 Million) as of November 1, 2026. Listed on the F stock exchange, this Germany-based company holds position #17964 globally and #1680 in its home market, demonstrating a 0.87% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shandong Xinhua Pharmaceutical Company Limited's stock price €0.58 by its total outstanding shares 195000000 (195.00 Million). Also see how efficiently does Shandong Xinhua Pharmaceutical Company L generate cash for how efficiently the company converts equity into cash flow.
Shandong Xinhua Pharmaceutical Company Limited Market Cap History (2015–2026)
Shandong Xinhua Pharmaceutical Company Limited market cap history from 2015 to 2026. Data shows growth from $5.77 Million to $132.23 Million (33.45% CAGR). Check XIN stock price for real-time trading data and today's change.
Shandong Xinhua Pharmaceutical Company Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shandong Xinhua Pharmaceutical Company Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Shandong Xinhua Pharmaceutical Company L (XIN) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.02x
Shandong Xinhua Pharmaceutical Company Limited's market cap is 0.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.55x
Shandong Xinhua Pharmaceutical Company Limited's market cap is 0.55 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $6.79 Million | $4.01 Billion | $122.27 Million | 0.00x | 0.06x |
| 2017 | $10.17 Million | $4.52 Billion | $209.59 Million | 0.00x | 0.05x |
| 2018 | $7.09 Million | $5.21 Billion | $250.83 Million | 0.00x | 0.03x |
| 2019 | $10.74 Million | $5.61 Billion | $299.97 Million | 0.00x | 0.04x |
| 2020 | $12.24 Million | $6.01 Billion | $324.86 Million | 0.00x | 0.04x |
| 2021 | $34.01 Million | $6.56 Billion | $348.55 Million | 0.01x | 0.10x |
| 2022 | $74.41 Million | $7.50 Billion | $411.19 Million | 0.01x | 0.18x |
| 2023 | $77.26 Million | $8.10 Billion | $496.51 Million | 0.01x | 0.16x |
| 2024 | $158.44 Million | $8.47 Billion | $470.02 Million | 0.02x | 0.34x |
| 2025 | $158.44 Million | $8.75 Billion | $289.89 Million | 0.02x | 0.55x |
Competitor Companies of XIN by Market Capitalization
Companies near Shandong Xinhua Pharmaceutical Company Limited in the global market cap rankings as of November 1, 2026. Also see how large is Shandong Xinhua Pharmaceutical Company L's balance sheet for a full breakdown of the balance sheet.
Key companies related to Shandong Xinhua Pharmaceutical Company Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.62 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of Shandong Xinhua Pharmaceutical Company Limited (2015–2026)
Market capitalization of Shandong Xinhua Pharmaceutical Company Limited from 2015 to today. Between 2015 and today, Shandong Xinhua Pharmaceutical Company Limited's market cap moved from $5.77 Million to $ 132.23 Million, with a yearly change of 33.45%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €132.23 Million | -16.55% |
| 2025 | €158.44 Million | 0.00% |
| 2024 | €158.44 Million | +105.08% |
| 2023 | €77.26 Million | +3.83% |
| 2022 | €74.41 Million | +118.77% |
| 2021 | €34.01 Million | +177.84% |
| 2020 | €12.24 Million | +14.01% |
| 2019 | €10.74 Million | +51.45% |
| 2018 | €7.09 Million | -30.27% |
| 2017 | €10.17 Million | +49.66% |
| 2016 | €6.79 Million | +17.79% |
| 2015 | €5.77 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Shandong Xinhua Pharmaceutical Company Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $132.23 Million USD |
| MoneyControl | $132.23 Million USD |
| MarketWatch | $132.23 Million USD |
| marketcap.company | $132.23 Million USD |
| Reuters | $132.23 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shandong Xinhua Pharmaceutical Company Limited
Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. The company offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand; and contract manufacturing service… Read more